Overview

  • Product name
    Anti-TACI antibody [1A1]
    See all TACI primary antibodies
  • Description
    Rat monoclonal [1A1] to TACI
  • Host species
    Rat
  • Tested applications
    Suitable for: Flow Cytmore details
  • Species reactivity
    Reacts with: Human
  • Immunogen

    Tissue/ cell preparation (Human) - human TACI transfected into rat RBL cells.

  • Positive control
    • Blood B cells.

Properties

Applications

Our Abpromise guarantee covers the use of ab16230 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
Flow Cyt Use a concentration of 5 µg/ml.

Levels or Taci are variable and often low in human blood.

 

 

 

ab18450 - Rat monoclonal IgG2a, is suitable for use as an isotype control with this antibody.

 

Target

  • Function
    Receptor for TNFSF13/APRIL and TNFSF13B/TALL1/BAFF/BLYS that binds both ligands with similar high affinity. Mediates calcineurin-dependent activation of NF-AT, as well as activation of NF-kappa-B and AP-1. Involved in the stimulation of B- and T-cell function and the regulation of humoral immunity.
  • Tissue specificity
    Highly expressed in spleen, thymus, small intestine and peripheral blood leukocytes. Expressed in resting B-cells and activated T-cells, but not in resting T-cells.
  • Involvement in disease
    Defects in TNFRSF13B are the cause of immunodeficiency common variable type 2 (CVID2) [MIM:240500]. CVID2 is a primary immunodeficiency characterized by antibody deficiency, hypogammaglobulinemia, recurrent bacterial infections and an inability to mount an antibody response to antigen. The defect results from a failure of B-cell differentiation and impaired secretion of immunoglobulins; the numbers of circulating B cells is usually in the normal range, but can be low.
    Defects in TNFRSF13B are a cause of immunoglobulin A deficiency 2 (IGAD2) [MIM:609529]. Selective deficiency of immunoglobulin A (IGAD) is the most common form of primary immunodeficiency, with an incidence of approximately 1 in 600 individuals in the western world. Individuals with symptomatic IGAD often have deficiency of IgG subclasses or decreased antibody response to carbohydrate antigens such as pneumococcal polysaccharide vaccine. Individuals with IGAD also suffer from recurrent sinopulmonary and gastrointestinal infections and have an increased incidence of autoimmune disorders and of lymphoid and non-lymphoid malignancies. In vitro studies have suggested that some individuals with IGAD have impaired isotype class switching to IgA and others may have a post-switch defect. IGAD and CVID have been known to coexist in families. Some individuals initially present with IGAD1 and then develop CVID. These observations suggest that some cases of IGAD and CVID may have a common etiology.
  • Sequence similarities
    Contains 2 TNFR-Cys repeats.
  • Cellular localization
    Membrane.
  • Information by UniProt
  • Database links
  • Alternative names
    • CD 267 antibody
    • CD267 antibody
    • CD267 antigen antibody
    • CVID antibody
    • CVID2 antibody
    • FLJ39942 antibody
    • MGC133214 antibody
    • MGC39952 antibody
    • OTTHUMP00000065442 antibody
    • TNFRSF 13B antibody
    • TNFRSF 14B antibody
    • TNFRSF13B antibody
    • TNFRSF13B protein antibody
    • TNFRSF14B antibody
    • TR13B_HUMAN antibody
    • Transmembrane activator and CAML interactor antibody
    • Tumor necrosis factor receptor 13B antibody
    • Tumor necrosis factor receptor superfamily member 13B antibody
    see all

References

This product has been referenced in:
  • Schwaller J  et al. Neutrophil-derived APRIL concentrated in tumor lesions by proteoglycans correlates with human B-cell lymphoma aggressiveness. Blood 109:331-8 (2007). Read more (PubMed: 17190854) »
  • Salzer U  et al. Mutations in TNFRSF13B encoding TACI are associated with common variable immunodeficiency in humans. Nat Genet 37:820-8 (2005). Read more (PubMed: 16007087) »
See all 3 Publications for this product

Customer reviews and Q&As

1-2 of 2 Abreviews or Q&A

Answer

Thank you for your enquiry. According to our records there were some quality issues around this time that led to the removal of various applications although the application of FACS by this antibody was not questioned. However, I am prepared to offer you a replacement vial. I have arranged for a replacement vial to be shipped to you (order number 137297). We have a vial in stock so the antibody will be with you shortly. We recommend that U266 cells are used as a positive control by FACS and the following protocol is adopted: Buffers: PBS 1% Formaldehyde (FA) keep at 4°C PBS 0.5% saponin keep at 4°C PBS 50 mM NH4Cl 1.33g NH4Cl for 500ml Complete medium 0.5% saponin 3 x 105 cells/sample Protocol 1-wash cells 1X in PBS 2-incubate in 0.5 ml PBS 1%FA, 15 min at RT under agitation 3-wash 1X with PBS 4-wash 1X with PBS-NH4Cl 5-wash 1X with PBS 6-incubate with the first antibody in complete medium + 0.5% saponin for 30 min at RT. 7-wash once with 1X PBS 0.5% saponin 8-incubate with the secondary antibody in complete medium + 0.5% saponin for 30 min (or more depending on secondary specification) at RT in the dark. 9-wash once with PBS 0.5% saponin 10-wash once with PBS 11-resuspend in 0.2 ml PBS 12- analyse with FACS

Read More

Answer

I'm sorry to hear the customer is experiencing problems in FACS with some of our antibodies, it is likely that the problem is protocol related. I have received this morning a detailed FACS protocol with details of the buffers to use and fixative to use for staining with ab17323 and am still waiting for this information from the source of the anti TAC1 antibody, my apologies. The positive control recommended for endogenous detection by FACS is U266 cells. Recommended FACS protocol with ab17323 Buffers: PBS 1% Formaldehyde (FA) keep at 4°C PBS 0.5% saponin keep at 4°C PBS 50 mM NH4Cl 1.33g NH4Cl for 500ml Complete medium 0.5% saponin 3 x 105 cells/sample Protocol 1-wash cells 1X in PBS 2-incubate in 0.5 ml PBS 1%FA, 15 min at RT under agitation 3-wash 1X with PBS 4-wash 1X with PBS-NH4Cl 5-wash 1X with PBS 6-incubate with the first antibody in complete medium + 0.5% saponin for 30 min at RT. 7-wash once with 1X PBS 0.5% saponin 8-incubate with the secondary antibody in complete medium + 0.5% saponin for 30 min (or more depending on secondary specification) at RT in the dark. 9-wash once with PBS 0.5% saponin 10-wash once with PBS 11-resuspend in 0.2 ml PBS 12- analyse with FACS I hope this information helps,

Read More

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"

Sign up